# OnCo record mismatch-repair-msi (pathway). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/pathways/mismatch-repair-msi/>
  a schema:BioChemEntity ;
  onco:kind "pathway" ;
  schema:identifier "mismatch-repair-msi" ;
  schema:name "Mismatch repair & microsatellite instability"@en ;
  schema:description "After DNA is copied, a proofreading crew fixes the letters the polymerase got wrong. Lose it and the genome fills with thousands of small errors, especially in repetitive stretches (microsatellites). Those errors make abnormal proteins that the immune system can see, which is why immunotherapy works so well in these cancers."@en ;
  schema:url <https://onco.cc/pathways/mismatch-repair-msi/> ;
  schema:dateModified "2026-09-09"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/DNA_mismatch_repair> ;
  schema:citation <https://doi.org/10.1126/science.aan6733> ;
  onco:tag "mechanism", "mechanics-atlas" ;
  onco:cancers <https://onco.cc/cancers/colorectal/>, <https://onco.cc/cancers/endometrial/>, <https://onco.cc/cancers/gastric/>, <https://onco.cc/cancers/tnbc/>, <https://onco.cc/cancers/pancreatic/>, <https://onco.cc/cancers/gallbladder/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/>, <https://onco.cc/technologies/cgp/>, <https://onco.cc/technologies/germline-testing/>, <https://onco.cc/technologies/histopathology-ihc/>, <https://onco.cc/technologies/colorectal-screening/>, <https://onco.cc/technologies/aspirin-cancer-prevention/>, <https://onco.cc/technologies/synthetic-lethality-approaches/> ;
  onco:targets <https://onco.cc/targets/pd1/>, <https://onco.cc/targets/ctla4/>, <https://onco.cc/targets/wrn/>, <https://onco.cc/targets/pdl1/> ;
  onco:drugs <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/dostarlimab/>, <https://onco.cc/drugs/nivolumab/>, <https://onco.cc/drugs/ipilimumab/> ;
  onco:pathways <https://onco.cc/pathways/mutagenesis-signatures/>, <https://onco.cc/pathways/antigen-presentation-immunoediting/>, <https://onco.cc/pathways/pd1-checkpoint/>, <https://onco.cc/pathways/synthetic-lethality-map/> ;
  onco:terms <https://onco.cc/terms/msi/>, <https://onco.cc/terms/lynch-syndrome/>, <https://onco.cc/terms/tmb/>, <https://onco.cc/terms/neoantigen/>, <https://onco.cc/terms/tumour-agnostic/>, <https://onco.cc/terms/mutational-signature/>, <https://onco.cc/terms/endometrial-molecular-classes/>, <https://onco.cc/terms/cms-subtypes/> .